China NMPA Drug Master File (DMF) Whitepaper

China NMPA Drug Master File (DMF) Whitepaper

Understanding China’s Drug Master File system is essential for manufacturers of pharmaceutical ingredients, excipients, and packaging materials planning market entry or supporting drug registrations in China.

This whitepaper provides a practical overview of the China NMPA Drug Master File (DMF) framework, including regulatory background, filing requirements, review timelines, and post-market obligations. It is designed for regulatory affairs, quality, and market-entry teams who need a clear understanding of how Drug Master Filing supports drug approval in mainland China.

Why the China DMF System Matters

China introduced the Drug Master File system in 2018 to replace the previous pre-market approval system for pharmaceutical components. The change aligns China more closely with international regulatory practices and allows confidential information about key drug components to be submitted separately from finished drug applications.

Drug Master Files contain detailed technical information about:

• Active pharmaceutical ingredients (APIs)
• Pharmaceutical excipients
• Drug packaging materials

This information is submitted to the National Medical Products Administration (NMPA) and referenced during the approval of finished pharmaceutical products.

For suppliers and drug manufacturers, the DMF system plays a key role in protecting intellectual property, supporting regulatory review, and enabling efficient collaboration between component suppliers and drug applicants.

What You Will Learn in This Whitepaper

This whitepaper provides a structured overview of the China DMF regulatory landscape and explains how companies can prepare for the filing process.

Topics covered include:

Regulatory Framework in China

• Roles of the NMPA and the State Administration for Market Regulation (SAMR)
• Evolution of China’s pharmaceutical regulatory system
• How Drug Master Filing fits into China’s drug approval pathway

The China Drug Master File System

• Definition and scope of DMFs in China
• Types of components covered, including APIs, excipients, and packaging materials
• Key advantages of the DMF system for suppliers and pharmaceutical companies

Drug Master Filing Process

• Authorization of an NMPA Legal Agent
• Creating an NMPA online account
• Obtaining a Pre-DMF number
• Preparing and submitting the DMF dossier
• Completeness assessment and technical review stages
• Expected timelines and review pathways

The whitepaper also outlines typical timelines for review, which may range from approximately 20 months for API independent review to around 24 months for bundled reviews of excipients and packaging materials.

Understanding the DMF Review Lifecycle

The DMF process includes multiple regulatory stages, including:

1. Authorization of an NMPA Legal Agent
2. Preparation of the DMF dossier and gap analysis
3. Submission and completeness review
4. Technical evaluation by the NMPA
5. Supplementary information requests
6. Final approval and activation status

Once technical review is successfully completed, the DMF receives Active (“A”) status, meaning the component can be referenced in approved drug applications in China.

The whitepaper explains how these stages interact with drug registration dossiers and how bundled technical review affects excipients and packaging materials.

Post-Market Responsibilities

Companies must also manage regulatory obligations after a DMF becomes active.

The whitepaper covers key post-market considerations, including:

• API renewal requirements (every five years)
• Managing post-approval changes
• Reporting obligations and annual reporting practices
• Maintaining quality and traceability across supply chains

Effective post-market management helps ensure continued regulatory compliance and supports the long-term availability of pharmaceutical products in China.

Who Should Read This Whitepaper

This resource is particularly relevant for:

• API manufacturers supplying the China market
• Excipients and pharmaceutical packaging manufacturers
• Regulatory affairs teams responsible for China submissions
• Pharmaceutical companies developing or registering drugs in China
• Market-entry teams evaluating China regulatory pathways

‍